Dr. Christine Dunne’s practice focuses on domestic and international patent drafting and prosecution, with an emphasis in the areas of organic chemistry, medicinal chemistry, drug discovery, cancer therapeutics and pharmaceuticals.
Prior to joining Cooley, Christine worked at Cetya Therapeutics as a research assistant developing selective HDAC inhibitors. Christine’s doctoral research at Colorado State University focused on the development of largazole, a potent HDAC inhibitor, and SAR studies for the development of potent and selective inhibitors. Library development of complex analogues included the synthesis of biological conjugates and dual therapeutics.
While at Northeastern University, Christine completed two co-ops at Novartis Institutes for BioMedical Research where she studied Metabolism and Pharmacokinetics, focusing on metabolite identification and ocular metabolism.